Login to Your Account



Other News To Note


Friday, December 10, 2010
PharmAthene Inc., of Annapolis, Md., said the FDA lifted the partial clinical hold imposed last year on Valortim, a fully human anti-toxin monoclonal antibody being developed for the prevention and treatment of inhalational anthrax, clearing the company to move forward with a Phase I intravenous dose-escalation study in the coming weeks, which Roth Capital Partners analyst Joseph Pantginis called an "encouraging event" for the company.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription